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Background: The recent development of eosinophil-targeting agents has raised enthusiasm for management of
patients with hypereosinophilic syndromes. Roughly half of anti-IL-5-treated patients with corticosteroid-responsive
lymphocytic (L-HES) and idiopathic disease variants can be tapered off corticosteroids. Potential consequences of
corticosteroid-withdrawal on clonal expansion of pre-malignant CD3-CD4+ T-cells associated with L-HES are a
subject of concern. Indeed, corticosteroid treatment inhibits T-cell activation and may lower blood CD3-CD4+ cell
counts. On the other hand, previous studies have shown that eosinophils support CD4 T-cell activation, suggesting
that targeted eosinophil depletion may negatively regulate these cells.
Objectives: Effects of eosinophils on CD4 T-cell activation in vitro were investigated as an indirect means of
exploring whether treatment-induced eosinophil depletion may affect pathogenic T-cells driving L-HES.
Methods: Helper (CD4) T-cells and CD3-CD4+ cells from healthy controls and L-HES patients, respectively, were
cultured in vitro in presence of anti-CD3/CD28 or dendritic cells. Effects of eosinophils on T-cell proliferation and
cytokine production were investigated.
Results: Eosinophils enhanced CD3-driven proliferation of CD4 T-cells from healthy subjects in vitro, while
inhibiting TCR-independent proliferation and IL-5 production by CD3-CD4+ T-cells.
Conclusions: While this study confirms previous work showing that eosinophils support activation of normal helper
T-cells, our in vitro findings with CD3-CD4+ T-cells suggest that eosinophil-depletion may favor activation and
expansion of this pathogenic lymphocyte subset. With the ongoing development of eosinophil-targeted therapy for
various eosinophilic conditions, the indirect consequences of treatment on the underlying immune mechanisms of
disease should be investigated in detail in the setting of translational research programs.
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Anti-IL-5Introduction
Hypereosinophilic syndromes (HES) are characterized by
eosinophil-mediated tissue and organ damage, occurring
in the setting of persistent hypereosinophilia [1]. Al-
though several HES variants have been defined on the
basis of pathogenic disease mechanisms, the majority of
patients are still classified as “idiopathic” HES. In
lymphocytic variant HES (L-HES), hypereosinophilia
develops in response to marked over-production of* Correspondence: froufoss@ulb.ac.be
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reproduction in any medium, provided the oreosinophilopoietic cytokines [most notably interleukin
(IL)-5] by clonally expanded T-cells that often bear a
CD3-CD4+ phenotype [2]. A small subset of patients
with L-HES may develop T-cell lymphoma years after
diagnosis, possibly in relation with occurrence of specific
cytogenetic abnormalities [3].
For patients with both idiopathic HES and L-HES,
corticosteroids (CS) represent first-line therapy [4]. Inter-
feron (IFN)-α is an alternative for those who are CS-
dependent or CS-resistant. Both treatment options target
T-cell functions and have the potential to reduce CD3-
CD4+ T-cell counts [2]. Treatment of HES is not curative
and must therefore be maintained long-term to prevent
the development of irreversible eosinophil-mediated organd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and development of drug-resistance are common.
The recent development of targeted eosinophil-specific
therapies has aroused enthusiasm for HES management.
Interleukin-5 is a key mediator involved in differentiation,
expansion, chemotaxis, activation, and survival of eosino-
phils. Because of restricted expression of the human IL-5
receptor α chain (IL-5Rα), monoclonal antibodies directed
against IL-5 or its receptor are expected to have a selective
impact on eosinophils [5]. The anti-IL-5 antibody, mepoli-
zumab, was recently shown to be an effective CS-sparing
and eosinophil-lowering agent in CS-responsive HES pa-
tients with both lymphocytic and idiopathic disease vari-
ants [6-8]. Roughly half of mepolizumab-treated patients
can durably be tapered off CS. Although this represents a
major step forward for patients with HES, withdrawal of
therapeutic agent(s) active on T-cells is a subject of con-
cern for patients with L-HES because of the pre-malignant
potential of CD3-CD4+ T-cells.
The perspective of eosinophil-targeted therapy for
HES has therefore raised new questions, one of which
pertains to the fate of pathogenic CD4 T-cells. The
present study was undertaken to explore this issue, with
a special focus on clonal CD3-CD4+ T-cells associated
with L-HES. The effects of eosinophils on CD4 T-cell
activation were investigated in vitro as an indirect means
of exploring potential consequences of treatment-
induced eosinophil depletion.
Material and methods
Patients and control subjects
For the in vitro co-culture studies, fresh blood was
drawn from healthy controls recruited within our insti-
tution for isolation of eosinophils and CD4 T-cells, and
generation of monocyte-derived dendritic cells (DC). For
experiments conducted on CD3-CD4+ T-cells, we used a
stock of peripheral blood mononuclear cells (PBMC)
previously obtained by cytapheresis from two patients
with L-HES (patients L-HES1,2), and stored in liquid ni-
trogen. The cells from these two patients were consid-
ered fully representative of L-HES-associated CD3-CD4+
T-cells, which have been shown to express an extremely
homogenous phenotype [9] and gene expression profile
[10]. The clinical history of one patient (L-HES1) has
been described previously (patient 3 in reference [9]);
she was off treatment at the time cytapheresis was
performed. Patient L-HES2 had interrupted corticoster-
oid monotherapy 48 hours prior to cytapheresis. All
subjects provided written consent, and this study was
approved by our Institutional Review Board.
Isolation of eosinophils and CD4 T-cells
Blood from healthy donors was subjected to density gradient
centrifugation using Lymphoprep (Lucron, ELITechGroup,Belgium). PBMCs were harvested and left at room
temperature overnight in RPMI (Lonza, Verviers,
Belgium) containing 10% fetal calf serum, Penstrep,
and glutamine (all from Life Technologies Europe,
Gent, Belgium) (RPMI-FCS), before purification of CD4
T-cells. The remaining cells were subjected to red-
blood-cell lysis on ice using NH4Cl 0.8%. Granulocytes
were re-suspended in PBS (Lonza) with EDTA (2mM)
and BSA (0.5%) (Sigma-Aldrich, St. Louis, MO), and
eosinophil isolation was performed at 4°C using a hu-
man Eosinophil Isolation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to manufacturer’s instruc-
tions (negative selection). Viability and degree of purifica-
tion of eosinophils were >95% as assessed by Trypan-Blue
and May-Grünwald-Giemsa staining. Eosinophils were
resuspended in RPMI-FCS at 2×106 cells per ml, and
activated in vitro for 18 hours (37°C, 5% CO2) prior to co-
incubation with CD4 T-cells, using human IgA (7,5 μg/ml)
(Sigma-Aldrich, human IgA from colostrum), and affinity-
purified goat anti-human IgA (10 μg/ml) (Gentaur). This
strategy was chosen to elicit eosinophil activation prior
to co-incubation with T-cells, thereby optimizing their
costimulatory properties.
Purified CD4 T-cells (healthy donors and L-HES pa-
tients) were obtained from PBMC using the human
CD4+ T cell Isolation Kit II (Miltenyi Biotec) according
to manufacturer’s instructions (negative selection). CD4
T-cells from patients L-HES1,2 were further subjected to a
Dynabeads CD3 kit (Invitrogen, Life Technologies) to
obtain purified CD3-CD4+ T cells. Purity of desired
cells was >95%.
Preparation of monocyte-derived dendritic cells
Monocytes were purified from healthy subject PBMCs using
the human CD14 MicroBeads kit (Miltenyi Biotec)
according to manufacturer’s instructions (positive selection).
CD14-positive cells were resuspended in RPMI-FCS
enriched with non-essential amino acids (NEAA, Lonza
Biowhittaker) (RPMI-FCS-NEAA) at 5×105/per ml, cultured
for 6 days at 37°C, 5% CO2, and fed twice with GM-CSF
(800 U/ml) and IL-4 (500 U/ml) (Gentaur, Kampenhout
Belgium). On day-6, LPS (100 ng/ml) (Sigma-Aldrich) was
added. DCs harvested on day-7 expressed a mature pheno-
type as assessed by flow cytometry (high expression of
CD80, CD86, CD83, HLA-DR).
Co-culture experiments
For healthy control co-culture experiments, eosinophils
and T-cells were autologous, and T-cells were activated
with pre-coated anti-hCD3ε (10 μg/ml in PBS, 30 μl per
well, overnight, 4°C) (R&D Systems, Minneapolis) and
soluble anti-CD28 (1 μg/ml) (Immunotech, clone 28.2).
For experiments using CD3-CD4+ cells (L-HES), we could
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Figure 1 L-HES-associated CD3-CD4+ T-cells do not express
IL-5Rα. CD3-CD4+ T-cells from patient L-HES1 stain negatively for
CD125w (grey histogram), similar to normal CD4 T-cells (white
histogram) (1a), whereas basophils stain positively for this receptor
(grey histogram, 1b), as expected. Identical results were obtained for
CD3-CD4+ T-cells from patient L-HES2 and a third patient with L-HES.
Harfi et al. Journal of Translational Medicine 2013, 11:112 Page 3 of 7
http://www.translational-medicine.com/content/11/1/112activation, as these cells do not respond to CD3 engage-
ment. They do, however, respond to costimulatory signals
(CD2 and CD28) provided by monocyte-derived LPS-
matured DC (i.e. TCR-independent activation), as demon-
strated previously [11]. For the present study, CD3-CD4+
T-cells were therefore activated with monocyte-derived DC
from healthy donors, and then co-incubated with eosino-
phils from the same donor.
Co-cultures were performed in 96-well flat-bottom
culture plates (Greiner Bio-one, Cellstar). For healthy
controls, CD4 T-cells (105 cells per well) and eosinophils
(2×105 cells per well for a 2/1 ratio, 105 cells for a 1/1
ratio, 5×104 for a 0.5/1 ratio, and 104 cells for a 0.1/1 ra-
tio) were co-cultured for 48 hours at 37°C, 5% CO2 in
RPMI-FCS. For L-HES co-cultures, CD3-CD4+ T-cells
(105 cells per well), LPS-matured DC (104 cells per well),
and eosinophils (2×105 cells per well) were cultured for
5 days at 37°C, 5% CO2 in RPMI-FCS-NEAA.
At the end of co-cultures, 1/ culture supernatants were
harvested and stored at −20°C for cytokine measure-
ments (ELISA), 2/ cells were assessed for membrane
antigen expression, and/or intracellular cytokine expres-
sion, and 3/ H3-thymidine was added (triplicate) for 18
hours to quantify proliferation.
Quantification of membrane-expressed antigens and
cytokine expression
Freshly thawed PBMC from L-HES patients and from 3
healthy controls were used to quantify expression of IL-5Rα.
Cells were stained with anti-CD3-FITC, anti-CD4-PerCP
and anti-CD125w-PE or the relevant isotype control.
Flow cytometry was also used at the end of co-cultures for
assessment of membrane antigen expression and intracellu-
lar cytokine expression by T-cells. All cell types (T-cells,
eosinophils, and DC) were readily distinguished on the
basis of their forward and side-scatter properties. A large
population of viable eosinophils with high side-scatter
(i.e. granularity) was clearly identified at the end of all
co-cultures. For surface antigen assessment, T-cells were
directly labeled with fluorochrome-conjugated antibodies
at the end of co-cultures (anti-CD3-FITC, anti-CD4-PerCP,
anti-HLA-DR-PE, anti-CD25-APC). For intracellular
cytokine quantification, cells were incubated with
Brefeldine A (10 μg/ml), phorbol 12-myristate 13-acetate
(PMA) (50 ng/ml) and the ionophore A23187 (100 ng/ml)
(all from Sigma) for 4 additional hours, stained with anti-
CD3-FITC and anti-CD4-PerCP, fixed and permeabilized
using the Caltag cell permeabilisation kit (LifeTechnologies),
then incubated with anti-IL-2-PE and anti-IL-5-APC.
Successful activation of T-cells was confirmed by demon-
strating increased CD69 expression in stimulated compared
to unstimulated cells. Acquisition was performed using a
FacsCanto II withDiva software (BectonDickinson, San José,CA) (gate on living cells). Antibodies were purchased from
BD/BD-Pharmingen.
Co-culture supernatants were thawed for cytokine mea-
surements using commercial kits for IL-5 (R&D,Quantikine)
and IL-2 (eBioscience, ready-set-go), used according to
manufacturer’s instructions.
Statistical analysis
All paired observations (proliferation, CD25 and IL-2






































































































Figure 2 Eosinophils enhance proliferation and CD25
expression of in vitro activated CD4 T-cells from healthy
controls. Purified CD4+ T-cells from healthy subjects were activated
with coated anti-CD3 and soluble anti-CD28 (1 μg/ml) antibodies for
48 hours, in absence and in presence of autologous IgA/anti-IgA
activated eosinophils. Cells were then cultured for an additional 18
hours with H3-thymidine to assess proliferation (n=8) (2a), washed
and stained with fluoro-conjugated antibodies for assessment of
membrane CD25 expression by flow cytometry (n=6) (2b), or
underwent brief re-stimulation with PMA and A23187 to assess
intracellular cytokine expression (n=10) (2c).
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test. For co-culture experiments with DC, results for the 3
conditions (T-cells versus T-cells + DC versus T-cells +
DC + eosinophils) were analysed with Kruskal-Wallis and
compared two-by-two using Wilcoxon rank sum exact
test.
Results and discussion
Eosinophil-specific therapeutic agents targeting IL-5 or
its receptor would not be expected to directly affect
CD4 T-cells, which are known not to express the IL-5
receptor [12]. We first established that this is also true
for CD3-CD4+ T-cells, showing that aberrant cells from
3 patients with L-HES stain negatively for the IL-5Rα
chain (Figure 1).
Therapeutic eosinophil depletion may however affect
CD4 T-cells indirectly, by interrupting cross-talk between
these two cell-types. To explore this eventuality, we first
investigated whether eosinophils affect in vitro activation
of CD4 T-cells from healthy subjects. CD4 T-cells were
cultured in presence of anti-CD3/CD28 antibodies for 48
hours, in absence and in presence of autologous IgA/anti-
IgA pre-activated eosinophils. Eosinophils consistently
and significantly increased T-cell proliferation (Figure 2a),
as assessed by H3-thmidine incorporation (median 15722
versus 174332 cpm, in absence and in presence of eosino-
phils respectively, p = 0.008). This effect was dose-
dependent, with proliferation increasing in parallel with
eosinophil-T cell ratios (Additional file 1: Figure S1).
Eosinophils also further increased membrane CD25
expression by CD4 T-cells (Figure 2b) (median proportion
of CD25+ CD4 T-cells 51.4 versus 86.1% in absence and in
presence of eosinophils respectively, p = 0.03). In contrast,
we did not observe a statistically significant effect on the
proportion of IL-2 (Figure 2c), or IL-5 (data not shown)-
expressing T-cells as assessed by flow cytometry, and
measurement of IL-2 in culture supernatants did not yield
reproducible results (not shown).
To more specifically address the fate of clonal T-cells
in L-HES patients treated with eosinophil-depleting
therapy, we set up cultures with CD3-CD4+ T-cells
from L-HES patients, in absence and in presence of
eosinophils. In these experiments, T-cell activation was
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costimulatory, TCR-independent signals to CD3-CD4+
cells [11]. Consistent with our previous work, DC in-
duced proliferation of CD3-CD4+ cells (Figure 3a) and
secretion of IL-5 (Figure 3b). Eosinophils consistently
and significantly reduced DC-induced proliferation of
the aberrant T-cells (median reduction 58%), as well as
IL-5 production (median reduction 93%). We previously
reported that DC-induced CD3-CD4+ T-cell prolifera-
tion and Th2 cytokine production involve IL-2/IL-2Rα
interactions [11]. We did not observe any reproducible
eosinophil-induced changes in IL-2 concentrations in cul-
ture supernatants (not shown), which were low or un-
detectable in all culture conditions, presumably due to
recapture by activated T-cells. Attempts to re-stimulate
the cells at the end of co-cultures for detection of


































































Figure 3 Eosinophils inhibit dendritic cell-induced activation of CD3-C
presence of LPS-matured dendritic cells from healthy subjects for 5 days, in
Proliferation was assessed on the basis of H3-thymidine incorporation (3a),
expression of activation markers CD25 and HLA-DR was assessed by flow c
and IL-5 concentrations (pg/ml) (3b, n=6), and bars show the standard erro
histograms show CD25 and HLA-DR expression on CD3-CD4+ T cells cultur
and with both dendritic cells and eosinophils (continuous bold line); resultthe majority of experiments; however, we did observe a
clear-cut decrease in the percentage of IL-2-positive and
IL-5-positive T-cells from patient L-HES1 when eosinophils
were added (Additional file 2: Figure S2). As for IL-2Rα,
CD3-CD4+ T-cells from patient L-HES1 showed increased
membrane expression in response to DC, and eosinophils
consistently lowered the percentage of positively stained
cells (Figure 3c).
Overall, these in vitro experiments suggest that eosino-
phils display differential effects on healthy activated CD4
T-cells, and on abnormal clonal CD3-CD4+ T-cells
found in L-HES.
The data presented herein with normal CD3/CD28-
activated CD4 T-cells, supports previous studies indica-
ting that eosinophils potentiate CD3-mediated T-cell
activation. Eosinophils have indeed been shown to sup-




































































D4+ T cells in vitro. Purified CD3-CD4+ T cells were cultured in
absence or in presence of IgA/anti-IgA-activated eosinophils.
IL-5 was measured in culture supernatants by ELISA (3b), and
ytometry (3c). Histograms represent mean proliferation (cpm) (3a, n=8)
r of the mean for each condition. For cytometry studies (3c),
ed alone (continuous fine line), with dendritic cells (dashed bold line),
s are representative of 3 independent experiments.
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dependent fashion [13-15]. It is therefore conceivable
that eosinophil depletion in clinical situations typically
associated with antigen-driven T-cell activation and
(hyper)eosinophilia, including allergic disorders, may
ultimately blunt these T-cell responses to some degree
in vivo. Our observation that CD4 T cell proliferation
progressively decreases in parallel with eosinophil con-
centrations indicates that tighter therapeutic control of
eosinophil levels in patients with reactive eosinophilia
may result in inhibition of other down-stream conse-
quences of pathogenic T cell activation.
The relevance of these observations for humans
receiving eosinophil-targeted therapy remains elusive.
Others have explored short-term (maximum 3 monthly
infusions) effects of anti-IL-5 treatment on normal CD4
T-cells in vivo, in patients with asthma, idiopathic HES,
and eosinophilic esophagitis [16-18]. Although these
studies suggest overall that therapeutic eosinophil deple-
tion has no significant effects on the biology of normal
CD4 T-cells, the observation period is short compared
to the prolonged requirement for treatment in patients
with allergic disorders and HES. Long-term in vivo
evaluation of CD4 T-cell biology in patients treated with
eosinophil-depleting therapy, together with longitudinal
in vitro quantification of pertinent antigen-specific
responses are warranted.
In contrast to normal CD4 T-cells, CD3-CD4+ Th2-
cell functions were consistently inhibited in vitro by
eosinophils in the present study. This may be related to
intrinsic properties of the CD3-CD4+ T-cells and/or their
reliance on TCR/CD3-independent, rather than TCR-
dependent, activation pathways. Indeed, studies reported
so far have shown a central role of HLA-DR, and thus
TCR engagement, in eosinophil-mediated activation of
T-cells [13-15]. Because L-HES-associated CD3-CD4+
cells lack membrane TCR/CD3 expression, they are un-
able to interact with MHC molecules, and our recent
study on their gene expression profile has shown re-
duced expression of numerous CD3-related intracellular
signaling molecules [10]. In contrast, these cells have
been shown to respond to costimulatory ligands [11],
some of which are expressed by eosinophils [14,19].
Eosinophil-derived signals may therefore affect down-
stream signaling pathways differently, depending on
whether the T-cells are activated through the TCR/CD3
complex or not. Besides reduced expression of many
CD3-associated genes, significant alterations in the
expression level of various other membrane-expressed
receptors and signaling pathways were observed in CD3-
CD4+ cells [10], some of which may be relevant with
regard to interactions with eosinophils.
Our findings suggest that eosinophils may actually play
a regulatory role on the global activation status of CD3-CD4+ T-cells. Should this be the case in vivo, eosinophil
depletion with eosinophil-targeted treatment may actu-
ally favor clonal T-cell outgrowth in some patients with
L-HES. Several patients with L-HES have been treated
with anti-IL-5 for several years in the setting of an open-
label study, but none have been reported to develop
T-cell lymphoma [8]. Although two patients with idio-
pathic HES enrolled in the study did develop lymphoma
during the observation period, neither of them had de-
tectable CD3-CD4+ T-cells. Long-term, longitudinal,
in vivo data on CD4 T-cells in patients with L-HES
receiving eosinophil-targeted therapy is currently un-
available. Absolute counts of abnormal T-cells in pa-
tients with L-HES were not systematically assessed
throughout the above-mentioned open-label study to as-
sess for clonal expansion, nor were TCR gene rearrange-
ment analyses performed on the entire cohort to check
for appearance of new T-cell clones. Our in vitro data
emphasize the need for punctilious in vivo assessment of
aberrant T-cell clones in the setting of long-term
eosinophil-targeting treatment protocols. Although the
risk of developing lymphoma in patients with L-HES is
low, careful clinical follow-up is warranted, regardless of
the chosen treatment strategy.
In conclusion, our data provide further evidence that
activated eosinophils interact directly with CD4 T-cells
and may affect their functions in diseases associated with
(hyper)eosinophilia. Additionally, in vivo, tissue-dwelling
eosinophils have been shown to interact with numerous
other immune and non-immune cell types thereby indir-
ectly affecting T cell functions [20]. With increasing op-
portunities to treat various eosinophilic conditions using
eosinophil-targeted therapy, special attention should be
paid to potential consequences of eosinophil depletion
on T-cell biology. Specifically, the present findings sug-
gest that eosinophils may restrain expansion of clonal
CD3-CD4+ T-cells associated with L-HES, perhaps con-
tributing to the indolent nature of this pre-malignant
disease. Future investigations should focus on the
eosinophil-derived mediators and surface molecules
affecting CD3-CD4+ T-cell proliferation and activation.Additional files
Additional file 1: Figure S1. Eosinophil-induced enhancement of CD4
T cell proliferation is dose-dependent. Purified CD4+ T-cells from healthy
subjects were activated with coated anti-CD3 and soluble anti-CD28
(1 μg/ml) antibodies for 48 hours, in absence and in presence of
autologous IgA/anti-IgA activated eosinophils at various eosinophil-T cell
ratios (0.1/1, 0.5/1, 1/1, and 2/1). Cells were then cultured for an
additional 18 hours with H3-thymidine to assess proliferation. A
statistically highly significant dose–response curve was observed when
comparing T-cells alone to T-cells cultured with eosinophils at
eosinophil/T cell ratios at 0.5/1 and 2/1 (Additional file 1: Figure S1a,
n=7). A statistically significant progression was also observed when
exploring additional ratios (Additional file 1: Figure S1b, n=4).
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http://www.translational-medicine.com/content/11/1/112Additional file 2: Figure S2. Eosinophils decrease the percentage of
CD3-CD4+ T-cells expressing IL-2 and IL-5. CD3-CD4+ T-cells from patient
L-HES1 were cultured alone, in presence of LPS-matured dendritic cells, or
in presence of both LPS-matured dendritic cells and eosinophils. On day
5, cells were harvested, washed, and re-stimulated with PMA+A23187 in
presence of brefeldine A for a further 4 hours. Cells were then surface-
stained with anti-CD3-FITC and anti-CD4-PerCP, fixed and permeabilised,
then stained for intracytoplasmic cytokine expression with anti-IL-2-PE
and anti-IL-5-APC. Acquisition for flow cytometry was performed on a
Facs Canto II, using DIVA software.
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